Tianyue Zhai

Dr. Tianyue Zhai

Hokkaido University
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
SGSoudeh Ghafouri-Fard
Soudeh Ghafouri-Fard
MFMohadeseh Fathi
Mohadeseh Fathi
Tianyue ZhaiTianyue Zhai
Tianyue Zhai
Mohammad TaheriMohammad Taheri
Mohammad Taheri
Peixin DongPeixin Dong
Peixin Dong
Pancreatic cancer is one of the most deadly neoplasms and the seventh major cause of cancer-related deaths among both males and females. This cancer has a poor prognosis due to the lack of appropriate methods for early detection of cancer. Long non-coding RNAs (lncRNAs) have been recently found to influence the progression and initiation of pancreatic cancer. MACC1-AS1, LINC00976, LINC00462, LINC01559, HOXA-AS2, LINC00152, TP73-AS1, XIST, SNHG12, LUCAT1, and UCA1 are among the oncogenic lncRNAs in pancreatic cancer. On the other hand, LINC01111, LINC01963, DGCR5, MEG3, GAS5, and LINC00261 are among tumor suppressor lncRNAs in this tissue. In the current review, we summarize the roles of these two classes of lncRNAs in pancreatic cancer and discuss their potential as attractive diagnostic and prognostic biomarkers for pancreatic cancer. We also identified that the low expression of MEG3, LINC01963, and LINC00261 and the high expression of MACC1-AS1, LINC00462, LINC01559, and UCA1 were significantly correlated with worse survival in pancreatic cancer patients. Further research on these lncRNAs will provide new clues that could potentially improve the early diagnosis, prognostic prediction, and personalized treatments of patients with pancreatic cancer.

7 April 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Tianyue ZhaiTianyue Zhai
Tianyue Zhai
IFItsuko Furuta
Itsuko Furuta
RARina Akaishi
Rina Akaishi
SISatoshi Ishikawa
Satoshi Ishikawa
MMMamoru Morikawa
Mamoru Morikawa
HMHisanori Minakami
Hisanori Minakami
Podocyte injury has been suggested to induce phenotypic alteration of glomerular podocytes and accelerate the detachment of podocytes from the glomeruli resulting in podocyturia. However, it is not clear whether podocyte phenotypic alteration occurs in the urine of women with preeclampsia (PE). Seventy-seven and 116 pelleted urine samples from 38 and 18 women at various stages of normal and PE pregnancies, respectively underwent quantitative analysis of podocyte-specific or associated protein mRNA expression, including podocin, nephrin, and synaptopodin using RT-PCR. Significant proteinuria in pregnancy (SPIP) is defined as protein:creatinine ratio (P/Cr, mg/mg) ≥0.27 in the urine supernatant. All three urine-pellet mRNAs expression levels were significantly positively correlated with P/Cr levels, suggesting that podocyturia increased with proteinuria. The podocin:nephrin mRNA ratio (PNR) and synaptopodin:nephrin mRNA ratio (SNR) increased significantly with increasing P/Cr, while the podocin:synaptopodin mRNA ratio (PSR) did not change significantly according to P/Cr, resulting in significantly higher PNR and SNR, but not PSR levels, in urine from PE women with than without SPIP. The PNR, SNR, and PSR in urine from PE women before onset of SPIP were comparable to those from controls. Thus, nephrin mRNA expression was reduced in the podocytes recovered from PE women.

12 November 2016 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
IFItsuko Furuta
Itsuko Furuta
Tianyue ZhaiTianyue Zhai
Tianyue Zhai
SISatoshi Ishikawa
Satoshi Ishikawa
TUTakeshi Umazume
Takeshi Umazume
KNKinuko Nakagawa
Kinuko Nakagawa
HMHisanori Minakami
Hisanori Minakami

19 April 2017 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
YBYosuke Baba
Yosuke Baba
IFItsuko Furuta
Itsuko Furuta
Tianyue ZhaiTianyue Zhai
Tianyue Zhai
AOAkihide Ohkuchi
Akihide Ohkuchi
TYTakahiro Yamada
Takahiro Yamada
HMHisanori Minakami
Hisanori Minakami

2 August 2016 in BMJ Open
Verified
Journal Article
Open access
PDF file
Tianyue ZhaiTianyue Zhai
Tianyue Zhai
IFItsuko Furuta
Itsuko Furuta
RARina Akaishi
Rina Akaishi
KKKosuke Kawabata
Kosuke Kawabata
KCKentaro Chiba
Kentaro Chiba
HMHisanori Minakami
Hisanori Minakami
Objectives To investigate the possibility of nephrinuria as a screening tool for the risk of pre-eclampsia (PE). Design Prospective observational study. Setting A single university hospital. Changes in urinary nephrin:creatinine ratio (NCR, ng/mg) and protein:creatinine ratio (PCR, mg/mg) in pregnancy were determined. Significant proteinuria in pregnancy (SPIP) was defined as PCR>0.27. PE was diagnosed in women with both SPIP and hypertension. Participants 89 pregnant women in whom neither hypertension nor SPIP was present at enrolment, providing 31, 125 and 93 random urine samples during first, second and third trimesters, respectively. Results PE developed in 14 of the 89 women. NCR increased with increasing PCR in 14 women with PE (correlation coefficient, 0.862; p122 (95th centile value for 75 women with normotensive pregnancies) was 5.93 (95% CI 2.59 to 13.6; 60% (6/10) vs 10% (8/79)) and 13.5 (95% CI 3.31 to 55.0; 75% (6/8) vs 5.5% (2/36)), respectively, compared with women with NCR≤122 at that time. Conclusions Nephrinuria was unlikely to increase in normal pregnancy. A certain NCR cut-off may efficiently differentiate women at higher risk of PE.

22 February 2023 in Cancer Medicine
Verified
Journal Article
Open access
Tianyue ZhaiTianyue Zhai
Tianyue Zhai
TMTakashi Mitamura
Takashi Mitamura
LWLei Wang
Lei Wang
SKShimpei I. Kubota
Shimpei I. Kubota
MMMasaaki Murakami
Masaaki Murakami
HWHidemichi Watari
Hidemichi Watari
Background: Anti‐angiogenic therapy with bevacizumab (BEV), an anti‐VEGF antibody, plays a critical role in the treatment of ovarian cancer. However, despite an encouraging initial response, most tumors become resistant to BEV over time, and a new strategy that enables sustainable treatment using BEV is therefore needed.Methods: To overcome the resistance to BEV in patients with ovarian cancer, we performed a validation study of combination therapy with BEV (10 mg/kg) and the CCR2 inhibitor BMS CCR2 22 (20 mg/kg) (BEV/CCR2i) using 3 consecutive patient‐derived xenografts (PDXs) of immunodeficient mice.Results: BEV/CCR2i demonstrated a significant effect of growth suppression in the BEV‐resistant serous PDX and BEV‐sensitive serous PDX compared with BEV (30.4% after the second cycle and 15.5% after the first cycle, respectively), and treatment cessation did not attenuate this effect. Tissue clearing and immunohistochemistry with an anti‐α‐SMA antibody suggested that BEV/CCR2i suppressed angiogenesis from the host mice more than BEV. In addition, human CD31 immunohistochemistry revealed that BEV/CCR2i decreased microvessels originating from the patients to a significantly greater degree than BEV. Regarding the BEV‐resistant clear cell PDX, the effect of BEV/CCR2i was unclear during the first five cycles, but the following two cycles of increased‐dose BEV/CCR2i (CCR2i 40 mg/kg) significantly suppressed tumor growth compared with BEV (28.3%) by inhibiting the CCR2B‐MAPK pathway.Conclusions: BEV/CCR2i showed a sustained anticancer immunity‐independent effect in human ovarian cancer that was more significant in serous carcinoma than in clear cell carcinoma.